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Abstract
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of cardiac myocytes 
that is characterized by cardiac hypertrophy, unexplained by the loading condi-
tions, a non-dilated left ventricle and a normal or increased left ventricular ejection 
fraction (LV-EF). Prevalence of HCM has been estimated at 0.16% to 0.29% (≈ 
1:625–1:344 individuals) in the general adult population. HCM represents the most 
common genetic heart disease and represent an archetypical single gene disorder 
with an autosomal dominant pattern of inheritance and historically termed a 
“disease of the sarcomere”. The precise mechanisms by which sarcomere variants 
result in the clinical phenotype have not been fully understood. Mutant sarcomere 
genes trigger several myocardial changes, leading to hypertrophy and fibrosis, 
which ultimately result in a small, stiff ventricle with impaired systolic and diastolic 
performance despite a preserved LV-EF. The most common differential diagnosis 
challenges in the presence of hypertrophic heart disease are represented by: ath-
lete’s heart, hypertensive heart and other cardiomyopathies mimicking HCM. A 
multimodality approach using ECG, echocardiography, CMR, cardiac computed 
tomography (CCT) and cardiac nuclear imaging provides unique information 
about diagnosis, staging and clinical profiles, anatomical and functional assess-
ment, metabolic evaluation, monitoring of treatment, follow-up, prognosis and 
risk stratification, as well as preclinical screening and differential diagnosis. HCM 
may be associated with a normal life expectancy and a very stable clinical course. 
However, about a third of patients develop heart failure (HF); in addition, 5–15% 
of cases show progression to either the restrictive or the dilated hypokinetic evolu-
tion of HCM, both of which may require evaluation for cardiac transplantation. 
The clinical course of HCM has been classified into four clinical stages: non-
hypertrophic, classic, adverse remodeling and overt dysfunction phenotype. No 
evidence-based treatments are available for non-hypertrophic HCM patients (pre-
hypertrophic stage), on the other hand in classic HCM, adverse remodeling and 
overt dysfunction phenotype, pharmacological or interventional strategies have the 
target to improve functional capacity, reduce symptoms, prevent disease progres-
sion. Therapeutic approach mainly differs on the basis of the presence or absence 
of significant obstructive HCM. Adult patients with HCM report an annual inci-
dence for cardiovascular death of 1–2%, with sudden cardiac death (SCD), HF and 
thromboembolism being the main causes of death; the most commonly recorded 
fatal arrhythmic event is spontaneous ventricular fibrillation. For this reason, SCD 
risk estimation is an integral part of clinical management of HCM. International 
guidelines suggest the evaluation of several risk factor for SCD based on personal 
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and family history, non-invasive testing including echocardiography, ambulatory 
electrocardiographic 24 hours monitoring and CMR imaging in order to identity 
those patients most likely to benefit implantable cardioverter-defibrillator (ICD) 
implantation. The present chapter summarize genetics, pathogenesis, diagnosis, 
clinical course and therapy of HCM as well as novel therapeutic options.
Keywords: hypertrophic cardiomyopathy, left ventricular hypertrophy, genetics, 
sudden cardiac death, heart failure, echocardiography, cardiac magnetic resonance, 
athlete’s heart, hypertrophic phenocopies
1. Definition and epidemiology
Cardiomyopathies are defined by structural and functional abnormalities of 
the ventricular myocardium that are unexplained by flow-limiting coronary artery 
disease or abnormal loading conditions [1]. Historically, cardiomyopathies has been 
subdivided into primary disease, in which the heart is the only involved organ, and 
secondary forms where the cardiomyopathy is a manifestation of a systemic disor-
der. Hypertrophic cardiomyopathy (HCM) is a genetic disorder of cardiac myocytes 
that is characterized by cardiac hypertrophy, unexplained by the loading condi-
tions, a non-dilated left ventricle (LV) and a normal or increased left ventricular 
ejection fraction (LV-EF) [2]. HCM is a disorder without a distinct geographic, 
ethnic or gender pattern of distribution. Prevalence of HCM has been estimated at 
0.16% to 0.29% (≈ 1:625–1:344 individuals) in the general adult population [2–5]. 
HCM is characterized by highly variable genotype–phenotype relationship with 
intra- and inter-family expressivity and incomplete penetrance. Given the age-
dependent expression of HCM mutations, its prevalence is expected to be higher 
in older subjects; in fact, HCM has been reported in 0.29% (1:333) of 60-year-old 
individuals undergoing echocardiography for cardiovascular evaluation. [2–5]. 
Moreover, a much higher estimate of 0.6% (1:167) has been suggested using more 
sensitive imaging methods, when family members are evaluated and when genetic 
testing is more widely used [6–8]. On the other hand, in children cardiac hypertro-
phy could result from the phenocopy conditions, which might account for 5% to 
10% of the clinically diagnosed HCM cases [9–11].
2. Genetics
HCM represents the most common genetic heart disease reported in popula-
tions globally. HCM is an archetypical single gene disorder with an autosomal 
dominant pattern of inheritance, whereby a single mutation is usually sufficient to 
cause the disease, albeit with variable penetrance and expression [12]. Autosomal 
recessive and X-linked modes of inheritance have been described but are rare 
[13, 14]. Approximately 60% of patients with HCM have a clearly recognizable 
familial disease. On the other hand, despite the great advances of the research in 
the field of genetics in cardiomyopathies, to date about 40% of HCM shows nega-
tive genetic testing or variants of non-certain significance. These data suggest that 
even non-genetic factors could contribute to the development of HCM. Moreover, 
a substantial proportion of patients with HCM are currently without any evidence 
of a genetic etiology to their disease, including a subgroup who also have no other 
affected family members (named “non-familial” HCM) [15]. For these reasons, the 
absence of an identified causative mutation should not allow to exclude a diagnosis 
in the presence of diagnostic criteria for HCM. Historically, HCM was termed a 
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“disease of the sarcomere” when the first three disease genes encoding components 
of the contractile apparatus of heart muscle were identified [16]. However, a wide 
variety of non-sarcomeric genes has been associated with HCM, thus suggesting 
that LV hypertrophy in HCM may not be a consequence of exclusive sarcomeric 
mutations. Among the known causal genes (Figure 1), thick myofilaments proteins 
such as MYH7 and MYBPC3 (myosin- binding protein C) are the 2 most common, 
together being responsible for approximately half of the patients with familial 
HCM [17–20]. On the other hand, mutations in thin myofilament proteins such 
as TNNT2, TNNI3 (cardiac troponin I) and TPM1 (α-tropomyosin) are relatively 
uncommon causes of HCM and together are responsible for less than 10% of cases 
[19–22]. Mutations in ACTC1 (cardiac α-actin), MYL2 (myosin light chain 2), 
MYL3 (myosin light chain 3), and CSRP3 (cysteine and glycine-rich protein 3) are 
also established, albeit uncommon, causes of HCM [23–25]. Moreover, mutations 
in TTN (titin), TCAP (telethonin), MYOZ2 (myozenin 2), TRIM63 (ubiquitin 
E3 ligase tripartite motif protein 63 or MuRF1), and FHL1 (four-and-a-half 
LIM domains 1) also have been implicated as causes of HCM but occur typically 
in sporadic cases and small families [26–33]. On the other hand, mutations in 
TNNC1 (cardiac troponin C), MYH6 (myosin heavy chain or α-myosin heavy 
chain), PLN (phospholamban), CAV3 (caveolin3), ALPK3 (α kinase 3), and JPH2 
(junctophilin-2) have also been reported in patients with HCM [34–39] but their 
causal role in HCM is less certain and has not been established unambiguously. An 
X-linked inheritance typically raises the possibility of a phenocopy condition, such 
as Fabry disease [40]. A phenocopy condition also occurs in syndromic diseases, 
such as the Noonan syndrome and in storage diseases, such as Anderson–Fabry 
disease. [41, 42]. Finally, a subset of HCM patients (≈5%) exhibits 2 (digenic) 
or more (oligogenic) causal mutations in the same gene or causal mutations in 
different genes [20, 43–51] and the severity of LV hypertrophy in subjects with 
Figure 1. 
HCM genetics and pathogenetic mechanisms. Center part: A schematic structure of a sarcomere composed of 
thick and thin filaments and Z discs is showed along with its protein constituents. Established causal genes for 
HCM and their relative population frequencies are listed. Panel A-D: HCM pathogenetic pathways (not be 
considered in isolation since they can act in concert). Panel a: Biomechanical stress sensing pathway. Panel B: 
Calcium cycling and sensitivity pathway. Panel C: Energy homeostasis pathway. Panel D: Fibrotic pathway. 
Abbreviations: LTCC, voltage-dependent L-type calcium channel; PLB, cardiac phospholamban; RyR2, 
ryanodine receptor 2; SERCA2, sarcoplasmic/endoplasmic reticulum calcium ATPase 2; SR, sarcoplasmic 
reticulum; TGF-β, transforming growth factor β; MITO, mitochondria.
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such mutations seems to be more pronounced [44–48]. The majority of the causal 
mutations in HCM are missense mutations which may alter protein structure and 
function by changing the amino acid composition of the encoding protein. The 
insertion/deletion mutations induce a frameshift in the encoded protein. Likewise, 
the premature truncated proteins are subsequently degraded by the ubiquitin 
proteasome system, leading to haplo-insufficiency [19, 20, 52]. The missing causal 
gene in HCM might be in part because of the difficulty in ascertaining the causal-
ity of the genetic variants, in an unambiguous manner, in the sporadic cases and 
small families [53]. In general, genetic variants exert highly variable biological 
consequences, ranging from large and causal to clinically negligible [54–56]. The 
demonstration of an association between a candidate gene and the HCM phenotype 
in a discovery population is considered provisional (ie, hypothesis-generating) and 
requires testing for replication in an independent population.
3. Pathogenesis
The precise mechanisms by which sarcomere variants result in the clinical 
phenotype have not been fully understood. Mutant sarcomere genes trigger several 
myocardial changes, leading to hypertrophy and fibrosis, which ultimately result 
in a small, stiff ventricle with impaired systolic and diastolic performance despite 
a preserved LV-EF [57]. On the other hand, abnormal sarcomeric proteins may not 
be solely responsible for all of the clinical characteristics observed in patients with 
HCM. Diverse disease features including abnormal intramural coronary arteries, 
responsible for small vessel ischemia, elongated mitral valve leaflets, as well as 
congenital anomalies of the sub-mitral valve apparatus, appear to have no known 
direct association with sarcomere mutations. From a metabolic viewpoint, muta-
tions in sarcomeric proteins generally increase myofilament activation and result 
in myocyte hypercontractility and excessive energy use [58] due to higher (dispro-
portionate) mitochondrial activity (Figure 1). Mitochondrial impairments in the 
cardiac energy-sensing apparatus (e.g., AMP-activated protein kinase [AMPK]) as 
well as alterations in calcium handling result in a stimulation of signaling pathways 
(e.g., the Janus-associated kinase–signal transducers and activators of transcription 
[JAK–STAT] signaling pathway) that contribute to myocyte relaxation abnormali-
ties and growth, with aberrant tissue architecture abnormalities such as myofibril-
lar disarray and myocardial fibrosis [59–62].
4. Diagnosis
4.1 Diagnostic criteria
In 2014 ESC Guidelines, HCM is defined by a wall thickness ≥ 15 mm in one or 
more LV myocardial segments - as measured by any imaging technique (echocar-
diography, cardiac magnetic resonance imaging (CMR) or computed tomography 
(CT) - that is not explained solely by loading conditions, thereby including both 
sarcomeric and non-sarcomeric mutations, such as other genetic disorders (inher-
ited metabolic and neuromuscular diseases, chromosome abnormalities) genetic 
syndromes and non-genetic disorders (e.g. senile-TTR and AL amyloidosis) [2]. 
On the other hand, in 2020 AHA Guidelines, HCM is defined as a disease state in 
which morphologic expression is confined solely to the heart and characterized 
predominantly by LVH (wall thickness ≥ 15 mm) in the absence of another cardiac, 
systemic, or metabolic disease capable of producing the magnitude of hypertrophy 
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evident in a given patient and for which a disease-causing sarcomere (or sarcomere-
related) variant is identified, or genetic etiology remains unresolved [57].
Genetic and non-genetic disorders can present with lesser degrees of wall 
thickening (13–14 mm). In these cases, the diagnosis of HCM requires evaluation of 
other features including family history, non-cardiac symptoms and signs, elec-
trocardiogram (ECG) abnormalities, laboratory tests and multi-modality cardiac 
imaging [2]. More limited LVH can be diagnostic in family members of HCM 
patients or with a positive genetic test [57]. Children, as in adults, the diagnosis of 
HCM requires an LV wall thickness more than two standard deviations greater than 
the predicted mean (z-score: defined as the number of standard deviations from the 
population mean) [63]. In first-degree relatives of HCM patients with unequivo-
cal disease (LVH ≥15 mm) the diagnosis is based on the presence of otherwise 
unexplained increased LV wall thickness ≥ 13 mm in one or more LV myocardial 
segments, as measured using any cardiac imaging technique [echocardiography, 
cardiac magnetic resonance (CMR) or CT].
4.2 Differential diagnosis: “from athlete’s heart to HCM phenocopies”
The most common differential diagnosis challenges in the presence of hypertro-
phic heart disease are represented by: athlete’s heart, hypertensive heart and other 
cardiomyopathies mimicking HCM.
4.2.1 Athlete’s heart
HCM is the most common cause of sudden cardiac death (SCD) among athletes 
[64]. Systematic and endurance training can lead to physiologic LV hypertrophy 
thereby mimicking mild forms of HCM [64]. Distinguishing between these two 
forms represents an important diagnostic dilemma during athlete cardiac evalu-
ation, thus a combination of anamnestical, clinical and instrumental data is 
crucial to distinguish the physiological hypertrophy seen in athlete’s heart from 
the pathological one seen in HCM. A positive family history of SCD represent an 
important factor that may point towards a genetic cardiomyopathy; similarly, ECG 
abnormalities such as ST depression, T wave inversion, abnormal Q waves or QRS 
axis increase the likelihood of HCM. On the other hand, isolated positive ECG 
criteria for hypertrophy are not enough to suspect HCM in the athlete. [64]. Even 
in the presence of septal thickness values suspected  for mild form of HCM (ranging 
form 14–16 mm), in the athlete’s heart echocardiogram generally presents several 
characteristics that are uncommon in HCM such as: normal or dilated LV volumes 
or normal systolic and diastolic function evaluated both with traditional methods 
(M-Mode or 2D) and with tissue Doppler or strain echocardiography. Moreover, a 
reduction in LV wall thickness after a period of deconditioning points to physiologi-
cal hypertrophy [65]. In some cases, further investigations such as exercise testing 
(arrhythmias or abnormal blood pressure response), 24 hours ECG monitoring 
(arrhythmias), CMR (fibrosis) or genetic testing (causative mutations) are needed 
to define the presence of HCM. Table 1 summarizes the clinical-instrumental 
aspects most useful in the differential diagnosis between HCM and athlete’s heart.
4.2.2 Hypertensive heart
Left ventricular hypertrophy secondary to arterial hypertension can be difficult 
to distinguish from mild forms of non-obstructive HCM caused by sarcomeric 
mutations; moreover an overlap between primary and secondary LV hypertrophy 























Athlete’s heart. None Uncommon Isolated LVH Not specific LVH symmetrical or eccentric 
(mild-to-moderate).




None Uncommon ST and T 
abnormalities
Not specific LVH: usually concentric (mild-to-moderate) Mild degree
No specific pattern
HCM AD Uncommon High LVH
ST and T 
abnormalities
Giant T wave 
inversion.
Q waves.
Not specific Moderate-to-severe LVH (asymmetrical and 
septal but potentially found at any location).
Diastolic dysfunction, the LVOT obstruction 
Mitral valve abnormalities (mitral SAM, 
leaflets elongation, dysplasia, prolapse, chordal 
elongation, laxity and hypermobility).
























Increased atrioventricular valve thickness
Increased RV free wall thickness
Global hypokinesia (with/without LV 
dilatation)
Frequent

















Increased interatrial septum thickness and 
atrioventricular valve thickness.









































































































mostly confined to the 
basal LV inferolateral wall
Table 1. 
HCM diagnosiss and differential diagnosis: “from athlete’s heart to HCM phenocopies”. Inheritance, signs or symptoms of multi-organ involvement, ECG abnormalities beyond LVH criteria, 
routine laboratory tests, echocardiographic and CMR main findings are shown for HCM and each phenocopies.
Cardiomyopathy - Disease of the Heart Muscle
8
Detailed arterial hypertension history and arterial blood pressure assessment as well 
as clinical evaluation of relatives may be crucial in distinguishing between hyper-
tensive heart and HCM. Moreover, a multimodality imaging approach is crucial in 
the differential diagnosis of HCM in hypertensive patients. Echocardiographic tissue 
doppler shows more impairment of diastolic function as well as lower early diastolic 
velocities in HCM [67, 68]. Similarly, two-dimensional (2D) strain echocardiography 
in HCM reveals a mid and apical short axis segments reduced radial strain as well as 
a reduced longitudinal strain in HCM with sarcomeric mutations [67, 68]. Moreover, 
myocardial fibrosis in CMR imaging as well as natriuretic peptides and troponin 
levels tend to be higher in HCM than in hypertensive heart [69].
4.2.3 HCM phenocopies
Significant advances and widespread availability of genetic testing at the same 
time have improved detection of the sarcomeric mutations that cause HCM but 
have also highlighted the significance of inborn errors of metabolism or metabolic 
storage disorders that can mimic HCM, named “HCM phenocopies” [70]. Five to 
ten percent of adult cases of HCM are caused by other genetic disorders including 
inherited metabolic and neuromuscular diseases, chromosome abnormalities, 
genetic syndromes as well as non-genetic disorders (e.g. TTR or AL amyloidosis) 
[71–74]. Whilst HCM phenocopies are relatively rare, it is crucial to distinguish 
these conditions at an early stage as their natural history, management, therapy and 
prognosis vary significantly from that of HCM with sarcomeric mutations. Table 1 
illustrates the salient features (red flags) of HCM phenocopies.
4.3 Multimodality imaging in HCM
Imaging techniques play an essential role in the evaluation of patients with HCM. 
A multimodality approach using ECG, echocardiography, CMR, cardiac computed 
tomography (CCT) and cardiac nuclear imaging provides unique information about 
diagnosis, staging and clinical profiles, anatomical and functional assessment, 
metabolic evaluation, monitoring of treatment, follow-up, prognosis and risk 
stratification, as well as preclinical screening and differential diagnosis (Figure 2).
ECG: is recommended at the first clinic visit in all individuals with known or 
suspected HCM and should be repeated whenever there is a change in symptoms 
in patients with an established diagnosis. It can be normal at presentation but 
generally shows a variable combination of LV hypertrohy (LVH), ST- and T-wave 
abnormalities and pathological Q-wave; ECG abnormalities that could mimicks 
other conditions, such as myocardial ischaemia or infarction, when interpreted 
together with echocardiography and CMR imaging findings, can suggest an under-
lying diagnosis or provide clues to the distribution of LVH and myocardial scar [75]. 
Moreover, since ECG abnormalities generally precede the development of LVH, 
periodic clinical and instrumental evaluations as well as family screening are useful 
even in the absence of conclusive diagnostic criteria. The frequency of arrhythmias 
detected during ambulatory electrocardiographic monitoring is age-related; asymp-
tomatic non-sustained ventricular tachycardia (NSVT) occurs in 25% of adults with 
HCM and for this reason a 24 or 48 hour Holter ECG represents a primary test for 
estimate the risk of SCD [2, 76–77].
Echocardiography: is the central imaging technique to the diagnosis and 
monitoring of HCM, given that identifies and quantify LVH that generally is 
asymmetric and involving the interventricular septum in the basal LV segments 
but often extends into the lateral wall, the posterior septum and LV apex [78]. In 
fact, increased ventricular wall thickness can be potentially found at any location. 
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Moreover, echocardiography estimates systolic and diastolic function, the presence 
of left ventricular outflow tract (LVOT) obstruction at rest and/or under provoca-
tive maneuvers such as Valsalva or standing, midventricular obstruction, mitral 
Figure 2. 
HCM: Inheritance and multimodality imaging. Panel A shows an HCM family pedigree with a MYH7+ 
mutation (autosomal dominant inheritance). The father and two of his children had HCM, another child was 
unaffected and was excluded from further clinical testing, and one child had a pathogenic mutation without 
LV hypertrophy. Black symbols denote affected family members, white symbols unaffected family members, 
squares male family members, and circles female family members; the arrow indicates the proband. The 
numbers under the symbols indicate age (in years) at the time of testing. Panel B shows ECG abnormalities 
in HCM characterized by: Short PR-interval, high QRS voltage, ST depression followed by diffuse giant T 
wave inversion. Panel C: HCM with extreme asymmetrical septal hypertrophy (45 mm – Echocardiography). 
Panel D: Apical HCM (echocardiography). Panel E shows HOCM with significant left ventricular outflow-
tract obstruction (74 mmHg peak gradient at echocardiography). Panel F shows a triphasic doppler inflow 
velocities with restrictive pattern in addition to L wave (arrow) in HCM patients with thin myofilament 
associated mutation (upper side). Tissue Doppler showing severe diastolic dysfunction characterized by low e’ 
(arrow) velocities (lower side). Panel G: Severe (24 mm) septal asymmetrical hypertrophy (arrow) in HCM 
(echocardiography). Panel H: Severe septal asymmetrical hypertrophy (arrow) in HCM (cardiac magnetic 
resonance). Panel I: HCM with fibrosis (cardiac magnetic resonance – LGE - arrow) at RV insertion points 
and intramural in the intraventricular septum. Panel L: HCM with diffuse and marked intramyocardial 
fibrosis (cardiac magnetic resonance – LGE - arrow) (Figure 3).
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valve abnormalities (mitral SAM, leaflets elongation with excessive tissue, dysplasia 
and prolapse, chordal elongation, laxity and hypermobility), atrial enlargement, 
or apical aneurysm [79]. Stress echocardiography can be used to detect myocardial 
ischemia, significant misunderstood LVOT obstruction, symptoms and blood pres-
sure response to exercise [80].
Cardiovascular magnetic resonance (CMR) imaging: provides detailed 
information on cardiac morphology, ventricular function and myocardial tissue 
characteristics [81]. CMR estimate left ventricle volumes, mass, ejection fraction 
as well as quantification, location, type and distribution of LVH but especially the 
visualization and quantification of myocardial fibrosis (LGE) [80].
In detection of myocardial ischaemia CCT is useful to evaluate the presence of 
epicardial coronary artery disease (CAD) in patients with HCM.
Single photon emission computed tomography/position emition tomography 
(SPECT/PET) myocardial perfusion imaging (using Thallium-201 and Tc-99 m 
labeled tracers) is useful to evaluate the presence of coronary microvascular 
dysfuntion showing reversible and fixed defects, thereby suggesting ischaemia and 
scar, with or without epicardial CAD detecting [82]. The assessment of myocardial 
metabolism can be performed through PET with F-18-fluorodeoxyglucose (FDG) 
or C-11-acetate, since an impairment in oxidative and glucose metabolism, mainly 
in the hypertrophic myocardium, has been found in HCM [83]. PET imaging has 
also been used to assess cardiac autonomic dysfunction, given that increased local 
catecholamine levels due to impaired neurotransmitter re-uptake into the cardiac 
nerve terminals, leading to decreased myocardial beta-adrenoceptor density, has 
been found in HCM [84].
Cardiopulmonary exercise testing (CPET): provides objective information 
about the severity of functional limitation, mechanisms responsible for symptoms 
during effort and plays a central role for cardiac transplantation indication [85]. 
CPET may be helpful in differentiating HCM from physiological ventricular hyper-
trophy since maximal oxygen consumption is normal or supra-normal in athlete’s 
heart and reduced in HCM. Moreover, CPET or conventional treadmill- or bicycle 
ergometry may be used in several contests: initial clinical evaluation, change in 
symptoms, LVOT gradient evaluation during effort, blood pressure response during 
exercise, detecting signs of myocardial ischemia caused by epicardial CAD and/or 
microvascular dysfunction [86–90].
5. Clinical course and disease stanging
HCM may be associated with a normal life expectancy and a very stable clinical 
course. However, about a third of patients develop heart failure (HF); in addition, 
5–15% of cases show progression to either the restrictive or the dilated hypokinetic 
evolution of HCM, both of which may require evaluation for cardiac transplanta-
tion [91, 92]. The clinical course of HCM has been masterfully classified by Olivotto 
et al. into four clinical stages: non-hypertrophic, classic, adverse remodeling and 
overt dysfunction phenotype [93] (Figure 3).
Non-hypertrophic HCM: is characterized by the absence of LVH in individuals 
with HCM-causing mutations identification during systematic family screenings. 
This stage of the disease is more frequent in newborn or very young children, while 
LVH tends to manifest during the second decade of life. However, due to incomplete 
penetrance and age-related onset, genotype-positive individuals can develop LVH 
as late as the 6th or 7th decade, and a significant minority seem to never develop 
the disease at all [94–96]. ECG, in this contest, is a fundamental tool to identify 
these patients since abnormalities can usually be evident even in the absence of LVH 
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on the echocardiogram [94]. Echocardiographic abnormalities may be found and 
includes impaired LV relaxation, mitral valve or subvalvar abnormalities, and mild 
degrees of left atrial enlargement. Although not diagnostic, these abnormalities 
may useful to suspect HCM in the context of familiar screening or ECG abnormali-
ties context [79–94]. CMR shows some degree of LV hypertrophy in about 16% of 
genotype-positive subjects with negative echocardiography. Prognosis of genotype-
positive individuals in this stage is unresolved, but presumed favorable [95, 96].
Classic HCM Phenotype: is defined as the phase in which the hypertrophic 
phenotype is fully expressed and the LV is hyperdynamic (as defined by an LV-EF 
>65%), without extensive fibrotic changes. LVH is typically regional and asym-
metrical, generally involving the basal septum and anterior wall, but can potentially 
involve any part of myocardial muscle such as right ventricle or papillary muscles 
[94–97]. Moreover, a large number of mitral valve, sub-valvar, subaortic, midven-
tricular abnormalities, atrial remodeling, coronary myocardial bridging, coronary 
microvascular dysfunction, crypts and autonomic nervous system abnormalities 
are present in this stage of the disease [79–99]. This stage is characterized by classic 
features such as myocardial disarray, microvascular remodeling, and interstitial 
fibrosis [95–101]. Most patients experience long periods of clinical stability without 
symptoms and may never undergo significant degrees of adverse remodeling or 
disease progression during their lifetime. Life expectancy is relatively favorable, 
with an annual cardiovascular mortality around 1% [94–102].
Adverse Remodeling Phenotype: is defined as the presence of structural 
modifications due to increasing LV fibrosis with worsening function (LV-EF 
50%–65%) associated with relatively preserved clinical and hemodynamic balance 
(15% to 20% of patients) [103–105]. The definition of this intermediate stage of 
disease progression is based on a combination of several structural and functional 
features including an LV-EF in the low-normal range [106], moderate to severe 
diastolic dysfunction [107, 108], marked atrial enlargement [109], moderate areas of 
LV fibrosis [94, 106–111], severe microvascular dysfunction [112], thinning of the 
Figure 3. 
Clinical stage and phenotypes of HCM: Prevalence, symptoms and main findings are separately shown for each 
stage of the disease.
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LV walls [103], onset of atrial fibrillation (AF) [113], spontaneous reduction or loss 
of LVOT obstruction [103–114], LV apical aneurysms [115] and variable patterns of 
intramyocardial fibrosis [116] that is inversely related to LV-EF.
Overt dysfunction HCM Phenotype: (5% of patients) is characterized by 
severe functional deterioration of the LV (LV-EF < 50%) secondary by extreme 
degrees of fibrosis and remodeling and generally associated with hemodynamic 
decompensation and adverse outcome [103, 105, 110, 117–119] with accelerated 
clinical deterioration of clinical condition. The morpho-functional manifesta-
tion of this stage can be summarized in two distinct and opposite phenotypical 
patterns: the hypokinetic-dilated form (LV dilation with spherical remodeling) 
[95, 110, 118, 119], that often may be hard to distinguish from a primary dilated 
cardiomyopathy, and the hypokinetic restrictive form (LV with small cavity and 
extreme diastolic dysfunction), mimicking a primary restrictive cardiomyopathy 
[94, 118–122]. In both forms, overt dysfunction represents the extreme conse-
quence of adverse remodeling and the outcome in this stage is severe, not only 
due to high rates of HF-related complications and mortality but also because of a 
considerable incidence of SCD [95, 118–123].
6. Management
No evidence-based treatments are available for non-hypertrophic HCM patients 
(pre-hypertrophic stage) and avoiding competitive activity may be considered in 
these individuals for the risk of development of HCM or SCD although this issue 
remains highly controversial [95, 124]. In classic HCM, adverse remodeling and 
overt dysfunction phenotype, pharmacological or interventional strategies have the 
target to improve functional capacity, reduce symptoms, prevent disease progres-
sion. Therapeutic approach mainly differs on the basis of the presence or absence 
of LVOT obstruction (HOCM). Patients with HCM who are asymptomatic and 
have no evidence of arrhythmias or LVOT obstruction at rest or on effort generally 
do not require medical treatment [125]. In symptomatic HOCM patients, the aim 
is to improve symptoms by using drugs, surgery, alcohol ablation or pacing. In 
symptomatic patients without LVOT obstruction, the target of therapy is to reduce 
arrhythmic risk, LV filling pressures as well as improve symptoms such as dyspnea 
and angina. Patients with progressive LV systolic or diastolic dysfunction refractory 
to medical therapy may be candidates for cardiac transplantation.
6.1 HOCM
LVOT obstruction is defined as a peak instantaneous Doppler gradient of 
≥30 mm Hg and the threshold for invasive treatment is usually considered to be 
≥50 mm Hg. In general, all HCOM patients should avoid dehydration and excess 
alcohol consumption, and weight loss should be encouraged. Arterial and venous 
dilators, such as nitrates and phosphodiesterase type 5 inhibitors, can exacerbate 
LVOT obstruction and should be avoided [126]. HOCM symptomatic patients 
can be treated initially with non-vasodilating ß-blockers titrated to maximum 
tolerated dose. If ß-blockers alone are ineffective, disopyramide can be added, 
titrated up to a maximum tolerated dose [127, 128] because can abolish basal LV 
outflow pressure gradients and improve exercise tolerance and functional capac-
ity without pro-arrhythmic effects [129–131]. Verapamil or ditiazem can be used 
when ß-blockers are contraindicated or ineffective [132–135]. Patients with HOCM 
(gradient ≥50 mm Hg,) and drug-refractory symptoms benefit from septal reduc-
tion therapy (SRT). Both septal myectomy and alcohol septal ablation (ASA) are 
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reasonable options when performed at experienced centres as part of a multidisci-
plinary team. Septal myectomy may be preferred when additional papillary muscle 
or mitral valve intervention can be performed, while ASA is favored for patients 
with elevated surgical risk [125]. Surgical myectomy has demonstrated excellent 
long-term efficacy and safety at selected high-volume centres with near-complete 
resolution of resting and inducible LVOT gradients. ASA showed similar periopera-
tive mortality (about 1%) when compared to myectomy [136], although associated 
with a 10–15% rate of complete heart block, repeat procedures and increased risk 
of scar-related ventricular arrhythmias [137, 138]. Moreover, ASA is dependent on 
coronary anatomy since 15% of patients had unsuitable septal perforators [139]. In 
experienced centres, selective injection of alcohol into a septal perforator artery (or 
sometimes other branches of the left anterior descending coronary artery) to create 
a localized septal scar has outcomes similar to surgery in terms of gradient reduc-
tion, symptom improvement and exercise capacity [140–144]. Even in absence of 
randomized trials comparing surgery and ASA, several meta-analyses have shown 
that both procedures improve functional status with a similar procedural mortality 
[145–148].
6.2 Symptomatic patients without LVOT
In patients with normal LV-EF and no evidence of resting or provocable LVOT 
obstruction, aim of therapy is to reduce LV diastolic pressures and improve LV 
filling by slowing the heart rate with b-blockers, verapamil or diltiazem and cau-
tious use of loop diuretics. Restoration of sinus rhythm or ventricular rate control 
is essential in patients who have permanent or frequent paroxysms of AF and 
digoxin is not recommended in patients with preserved EF because of the poten-
tially adverse effects of positive inotropic stimulation [149]. ß-Blockers or calcium 
antagonists should be considered in patients with exertional or prolonged episodes 
of angina-like pain. Both classes improve diastolic function, reduce myocardial 
oxygen, thereby improving stress-induced sub-endocardial perfusion defects 
[150–154]. Patients with reduced LV-EF and HF symptoms should be treated with 
diuretics, ß-blockers, angiotensin-converting enzyme (ACE) inhibitors, angioten-
sin receptor blockers (ARB) and mineralocorticoid receptor antagonists (MRA) 
according to ESC guidelines for the management of chronic heart failure [155]. 
Moreover, CRT may be considered in individual patients with refractory symptoms, 
LV-EF < 35% and LBBB (QRS duration 120 ms) in accordance with current ESC 
Guidelines [156]. On the other hand, since LV-EF < 50%, rather than <35% as in pri-
mary or secondary dilated cardiomyopathies, is a strong discriminator of end-stage 
disease (associated with deteriorating HF and SCD) there is clear need for HCM 
disease-specific CRT and CRT-D criteria [57].
Orthotopic cardiac transplantation should be considered in patients with 
moderate-to-severe drug refractory symptoms (NYHA functional Class III–IV) and 
no LVOTO who meet standard eligibility criteria [157].
6.3 Management atrial fibrillation and anticoagulation therapy
Atrial fibrillation (AF) is the most frequent arrhythmia in HCM, affecting 
more than 20% of patients, and represents a marker of unfavorable prognosis, 
particularly when associated with LVOT obstruction and in patients younger 
than 50 years of age; moreover, the onset of AF worsens symptoms related to HF 
[158–160]. In haemodynamically stable patients, oral b-blockers or non-dihydro-
pyridine calcium channel antagonists are recommended to slow the ventricular 
response to AF [161, 162]. Given the high incidence of stroke in patients with 
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HCM and paroxysmal, persistent or permanent AF, the current European Society 
of Cardiology (ESC) Guidelines of Atrial Fibrillation invite to do not use the 
CHA2DS2-VASc score to calculate stroke risk recommend that all patients with 
AF should receive treatment with OAC [163]. Similarly, the American Heart 
Association and American College of Cardiology (AHA/ACC) Guidelines recom-
mended use direct-acting oral anticoagulants (NOAC) as first-line option and 
vitamin K antagonists as second-line option [57].
6.4 Prevention of sudden cardiac death
Adult patients with HCM report an annual incidence for cardiovascular death 
of 1–2%, with SCD, HF and thromboembolism being the main causes of death; the 
most commonly recorded fatal arrhythmic event is spontaneous ventricular fibril-
lation (VF), but asystole, AV block and pulseless electrical activity are described 
[2]. For this reason, SCD risk estimation is an integral part of clinical management 
of HCM [164]. Younger HCM patients are at higher risk for SCD than older patients 
[30, 165–171] since the 5-year cumulative proportion of SCD events is 8–10% from 
diagnosis in childhood HCM [172, 173]. In secondary prevention (patients which 
experiment cardiac arrest due to VT or VF or spontaneous sustained VT causing 
syncope or haemodynamic compromise), implantable cardioverter-defibrillator 
(ICD) implantation is indicated in all HCM patients. On the other hand, in primary 
prevention the best strategy to evaluated SCD risk seems to be a multiparametric 
approach. Recently, AHA/ACC guidelines suggest the evaluation of several risk 
factor for SCD based on personal and family history [165, 174–176], noninvasive 
testing including echocardiography [174, 177–179], ambulatory electrocardio-
graphic 24 hours monitoring [180, 181] and CMR imaging [180–186] in order to 
identity those patients most likely to benefit ICD implantation [33, 168–170, 174, 
187]. On the other hand, ESC guidelines [2] have proposed a risk score, named 
HCM Risk-SCD, that includes both clinical and instrumental data, thereby predict-
ing annual risk of SCD and suggesting indication for ICD implantation (Table 2). 
Subcutaneous ICD (S-ICD) may be considered in HCM patients who have no indi-
cation for pacing especially in patients that have a long life expectancy. However, 
particular attention should be paid to ensuring optimal R-wave sensing to avoid 
inappropriate shocks [2].
6.5 New therapy prospective
Novel therapeutic options are being evaluated and validated with diversified 
targets in the context of the physiopathology of hypertrophic cardiomyopathy.
Myocardial Contractility and energetics: Hypercontractility appears to play 
a central role in the pathogenesis of HCM since the vast majority of known muta-
tions affect sarcomeric proteins, and ∼70% of identifiable mutations involving 
cardiac beta-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC) 
that contain the ATPase involved in actin–myosin cross bridging and muscle fiber 
shortening, thereby serving as the molecular motor for myocardial contraction 
[188–191]. It has been hypothesized that HCM mutations increase net power gen-
eration by the sarcomere resulting in LV hypercontractility and stiffening that is 
clinically observed. Mavacamten, a selective allosteric inhibitor of myosin ATPase 
capable of reducing the formation of bridges between actin and myosin at the 
sarcomere level and therefore of reducing contractility and improving the energy 
profile of the myocardium, helps ventricular hyper-contractility which has a patho-
physiological role determinant in the genesis of the dynamic obstruction to the left 








































SCD risk factor Definition AHA/
ACC
ESC
Clinical and anamnestical data Family history of SCD Sudden death judged definitively or likely attributable to HCM in ≥first-degree or close 
relatives who are 50 years of age.
X X
Age The effect of age on SCD is incremental. No data with age < 16 or > 80 X
Unexplained syncope ≥1 Unexplained episodes involving acute transient loss of consciousness, judged by history 
unlikely to be of neurocardiogenic etiology, nor attributable to LVOTO, and especially when 
occurring within 6 months of evaluation (events beyond 5 years in the past do not appear to 
have relevance).
X X
24 ECG monitoring NSVT NSVT with runs frequent (≥3), longer (≥10 beats), and faster (≥200 bpm) occurring usually 
over 24 to 48 hours of monitoring. For pediatric patients, a VT rate that exceeds the baseline 
sinus rate by >20%.
X X
Echocardiographic data Massive LVH Wall thickness ≥ 30 mm in any segment within the chamber by echocardiography or 
CMR imaging; consideration for this morphologic marker is also given to borderline 
values of ≥28 mm in individual patients at the discretion of the treating cardiologist. For 
pediatric patients with HCM, an absolute or z-score threshold for wall thickness has not 
been established; however, a maximal wall that corresponds to a z-score ≥ 20 (and > 10 in 
conjunction with other risk factors)
X X
LV systolic dysfunction Systolic dysfunction with EF ≤ 50% by echocardiophy or CMR imaging X
LV apical aneurism Apical aneurysm defined as a discrete thin-walled dyskinetic or akinetic segment of the most 
distal portion of the LV chamber; independent of size.
X
Left atrial diameter Left atrial diameter as determined by M-mode or 2D echocardiography in the parasternal long 
axis plane at the time of evaluation
X
LVOT Maximum LV outflow gradient determined at rest and with Valsalva provocation (irrespective 
of concurrent medical treatment)
X
Ergometric data Exercise blood pressure 
response
A failureto increase systolic pressure by at least 20 mmHg from rest to peak exercise or a fall of ˃ 













SCD risk factor Definition AHA/
ACC
ESC
CMR Extensive LGE Diffuse and extensive LGE, representing fibrosis, either quantified or estimated by visual 
inspection, comprising ≥15% of LV mass (extent of LGE conferring risk has not been 
established in children).
X
Recommendations for ICD implantation in primary prevention
AHA/ACC ESC (HCM Risk-SCD score)
ICD is reasonable (2A) with at least one of the following:





• NSVT (in children)
ICD may be considered (2B) with at least one of the following:
• NSVT in adults
• Extensive LGE
• LOW RISK (5-year risk < 4%): ICD generally not indicated
• INTERMEDIATE RISK (5-year risk 4–6%): ICD may be indicated
• HIGH RISK (5-YEAR RISK ≥ 6%): ICDshould be indicated
Table 2. 
Sudden cardiac death risk factors: Type, definition, AHA/ACC and ESC guidelines criteria for SCD risk assessment in primary prevention (upper side). Recommendations for ICD implantation 
in primary prevention according to AHA/ACC and ESC guidelines, separately (lower side).
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obstruction to the outflow and quality of life in patients with HOCM. Therefore, 
Mavacamten represents a valid new therapeutic option (but still not available) for 
patients with HCM and severe obstruction to the outflow tract despite maximal 
doses of beta-blocker, calcium channel blockers and disopyramide and before opt-
ing for a surgical approach [192].
Ion channels Regulation. HCM is associated with enhanced late sodium 
current (iNaL) activity due to enzyme-induced sodium-channel phosphorylation 
which results in increased intracellular sodium (Na+), and in turn, calcium (Ca2+) 
overload through ion exchange [193]. Dysregulated Ca2+ and Na + handling may 
contribute to altered cardiomyocyte mechanics (hyper-contractility and impaired 
relaxation) and predispose the myocardium to arrhythmias. Ranolazine is an 
inhibitor of iNaL with several potential beneficial effects in HCM, mainly related to 
the improvement in myocardial relaxation and both anti-ischemia and arrhythmia 
effects [193]. Although a open-label study (RHYME, NCT01721967) demonstrated 
positive effects on clinical outcomes, data from a phase II trial (RESTYLE-HCM) 
failed to demonstrate a significant effect on objective measures (peak VO2, serum 
B-type natriuretic peptide, diastolic function), while a reduction in premature 
ventricular complex burden [194] has been reported. For these reasons, ranolazine 
still remains an intriguing area of research in the field of HCM therapeutic options.
Fibrosis. Several therapies have attempted to address fibrosis and disease pro-
gression in HCM, although nowadays no drug has shown convincing benefits, this 
target represents an interesting field of research in cardioyopathies. While losartan, 
valsartan and spironolactone was demonstrated to be ineffective [195–198], atorv-
astatin demonstrated effects on suppression of hypertrophy in pre-clinical models 
[199] but had no effect and poor treatment adherence in a small early feasibility 
study in humans [200].
Genome editing and gene silencing. Advances in genome editing technology 
have sparked excitement about the potential for therapeutic use in cardiovascular 
disease; however, there remain important hurdles prior to implementation in clini-
cal practice [201, 202]. Current techniques including CRISPR/Cas9 cause a double-
stranded DNA break at a desired genetic locus followed by intrinsic cellular repair 
that is virtually error-free and recently, high-fidelity gene repair in human embryos 
carrying HCM mutations was shown to be feasible [203]. Using sperm from a het-
erozygous MYBPC3 mutation carrying male patient, oocytes from healthy women 
were inseminated. Simultaneous injection of a mutation-specific CRISPR/Cas9 
system during early metaphase resulted in editing of the mutation 100% of the time 
[204]. Allele-specific gene silencing is another gene-based therapeutic technology 
that holds promise for monogenic diseases. This typically involves the transduction 
of an adenovirus vector containing short-interfering ribonucleic acid segments 
designed to suppress expression of a specific pathogenic allele – a method more 
broadly defined as ribonucleic acid interference (RNAi). In pre-clinical models, 
RNAi was demonstrated to attenuate the phenotype of specific mutations causing 
catecholaminergic polymorphic ventricular tachycardia [205], HCM [206] and 
restrictive cardiomyopathy [207].
Cardiomyopathy - Disease of the Heart Muscle
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